Pharmaceutical intermediates
Fezolinetant Intermediates
6 pharmaceutical intermediates for Fezolinetant. Indication: Vasomotor Symptoms; Hot Flashes.
About Fezolinetant
- Originator
- Ogeda SA
- Indication
- Vasomotor Symptoms; Hot Flashes
- Approved Date
- 05/12/2023
- NCE Patent
- 05/12/2028
- DS/DP
- 04/04/2031
Available intermediates
6 intermediates currently listed for Fezolinetant. Request specifications, documentation or a quotation for any item below.
| Product Name | CAS No. | Molecular Formula | Physical Properties |
|---|---|---|---|
| 3-Methyl-1,2,4-thiadiazole-5-carbohydrazide | 1375066-73-1 | / | / |
| (R)-3-Methylpiperazin-2-one | 922178-61-8 | / | / |
| (R)-4-(2,4-diMethoxybenzyl)-3-Methylpiperazin-2-one | 1383146-20-0 | / | / |
| 3-Methyl-piperazin-2-one | 23936-11-0 | / | / |
| 5-bromo-3-methyl-1,2,4-thiadiazole | 54681-68-4 | / | / |
| 3-Methyl-[1,2,4]thiadiazole-5-carboxylic acid ethyl ester | 76162-56-6 | / | / |
Building toward Fezolinetant?
Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.
How can we help you?
Receive insights into the latest events and regulatory updates
Sent directly to your email
Get industry insights and Unibest news here
Contact Us →